The takeaway
Amneal Pharmaceuticals, Inc. Class A Common Stock shows a moderate seasonal pattern over 10 years of data — strongest in August (+2.4%) and softest in June (−4.0%).
Right now
In July, the stock has fallen 60% of years, averaging −0.1%, roughly 2.2 pts behind the S&P 500.
The full picture
Amneal Pharmaceuticals, Inc. Class A Common Stock's most dependable month has been August, higher in 6 of 10 years; June has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in May (+3.0 pts); it has trailed the market most in November (−6.8 pts).
“vs S&P” is Amneal Pharmaceuticals, Inc. Class A Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Amneal Pharmaceuticals, Inc. Class A Common Stock’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, August has closed higher 80% of the time versus 60% across the last 10 years — the pattern is strengthening.
Figures are the typical (median) August return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
There's a real but measured seasonal tilt here, toward August — the firmest corner of the calendar, higher in 6 of 10 Augusts.
The strength looks broad-based rather than freakish: its average (+2.4%) and median (+16.5%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even August ranges by 23.8% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — August has outpaced the S&P 500 by +2.1 points on average.
It doesn't stand entirely alone — February and July have leaned firm as well, if less emphatically. The weaker half of the year is plainer: June has been the soft spot — the weakest of 6 months that average a loss (−4.0%), and the edge isn't year-round — the stock has trailed the S&P 500 in November, October, and June. Its roughest month on record was a −48.5% July in 2019 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Augusts run ahead of the earlier years.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (August), its worst (June), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2016 its best month (August, +2.4%) has run well ahead of its worst (June, −4.0%) — the heatmap above shows how steady that gap has been year to year.
August has been the strongest, averaging +2.4% and closing higher in 6 of 10 years since 2016.
It's the weakest, averaging −4.0% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade